Bafna Pharmaceuticals, a manufacturer and exporter of drug formulation posted a net rise of 176.47 % in third-quarter ended 31st December 2009. The Sales for December 2009 quarter increased by 35.05 % to Rs 1974.45 lakh compare to Rs 1461.96 lakh in corresponding quarter of previous year ended December 2008. The net Profit for December 2009 has bounced back to Rs. 85.19 lakh compare to net loss of Rs 111.39 lakh in corresponding previous quarter of last year. The company announced its Third quarter results ended 31st December 2009.
During the quarter the company has got the approval to launch its first brand product of Olmesartan Medoxomil named “OLMEBAF” in Sri Lanka. The company is all set to market the brand by early 2010. Bafna Pharma is the only Indian company to market the branded product in the Sri Lanka market for the treatment of hypertension.
Source: Moneycontrol.comCourtesy moneycontrol.com
Also check
Posts
No comments:
Post a Comment